Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

Share Price is delayed by 15 minutes
Get Live Data
160.00    0.00 (0.00%)
Bid:
120.00
Ask:
200.00
Spread: 80.00 (66.667%)
Market Cap: £77.39m
SPSC Live PriceLast checked at - London Stock Exchange

Intraday Spectra (di/ S) Share Chart

Executed Contract with HMRC for Vaping Duty Stamps

5 Feb 2026 07:00

RNS Number : 7858R
Spectra Systems Corporation
05 February 2026
 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

5, February 2026

Spectra Systems Corporation

Executed Contract with HMRC for Vaping Duty Stamps Scheme

Further to the RNS dated 16 January 2026, Spectra Systems Corporation, a leader in machine-readable high speed banknote authentication, security printing, brand protection technologies and gaming security software, is pleased to announce that its security printing arm, Cartor Security Printers ("CSP"), has executed the contract with HMRC for production and supply of vape duty stamps. CSP was the primary on the contract, which was submitted in partnership with SICPA SA, a world leader in tax stamp track and trace technology.

The total estimated contract value is estimated to be £32M ($43.8M) excluding VAT and is based on five years and has an option for an additional year. Under the finalized executed contract terms, Spectra will be providing additional services and now expects its portion of the contract value to be approximately 22% of the total five-year revenue. As the lead in the contract, Spectra will be receiving entire $43.8M of revenue and dispersing the funds accordingly. Within the CSP-led consortium, CSP will be responsible for production and supply of stamps as well as high level forensic authentication features and associated devices provided by Spectra in Rhode Island, USA. Our partner will be responsible for additional security features, tax stamp coding, along with the track and trace software solution, managing stakeholder and product registration, tax stamp ordering, making payments and collecting data and monitoring compliance for HMRC relating to the vape products' entire journey through the supply chain.

Dr. Nabil Lawandy, CEO of Spectra Systems, stated: "We are delighted to have finalized this important new contract as we continue our re-organization of the security printing business to boost profits through longer term contracts. With the first phase of the reorganization having been completed in the UK facility, we are confident that with, this new prestigious contract win, we expect to see significant profits from CSP in 2026 and more so in 2027 when the entire benefit of the restructuring is in full operation."

The person responsible for arranging the release of this announcement on behalf of the Company is Dr. Nabil Lawandy, Chief Executive Officer of the Company.

Enquiries:

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer

Tel: +1 (0)401 274 4700

 

Zeus (Nominated Adviser and Joint Broker)

James Joyce / James Bavister/ Andrew de Andrade (Investment Banking)

 

 Allenby Capital Limited (Joint Broker)

Nick Naylor/James Reeve (Corporate Finance)

Amrit Nahal (Sales and Corporate Broking) 

Tel: +44 (0)20 3829 5000

 

 

 

Tel: +44 (0)20 3328 5665

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTFZLLBQLLXBBQ
Date   Source Headline
21st Mar 202311:44 amRNSDividend Record Date
20th Mar 20237:00 amRNSAudited results for year ended 31 December 2022
16th Mar 20234:35 pmRNSExercise of Options
6th Mar 202310:39 amRNSRemoval of Reg S restrictions from common stock
11th Oct 20226:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSContract Amendment to a Central Bank
21st Sep 20227:00 amRNSExercise of Options
12th Sep 20227:05 amRNSAppointment of Non-Executive Director
12th Sep 20227:00 amRNSInterim Results for Six Months Ended 30 June 2022
16th Aug 20227:00 amRNSFirst Banknote Disinfection System Sold
15th Aug 20227:00 amRNSNew Central Bank Contract Amendment
28th Jul 20227:00 amRNSShare Buy-Back
1st Jul 20222:31 pmRNSShare Buy-Back
28th Jun 20227:00 amRNSShare Buy-Back
15th Jun 20227:00 amRNSAdditional Central Bank Development Revenues
14th Jun 20227:00 amRNSAppointment of Chief Financial Officer
13th Jun 20227:00 amRNSAnnual General Meeting Update
25th May 20227:00 amRNSExercise of Options and Director/PDMR Shareholding
20th May 20228:44 amRNSRemoval of Regulation S restrictions from shares
20th May 20228:41 amRNSResignation of Chief Financial Officer
3rd May 20227:00 amRNSPosting of Annual Report & Notice of AGM
6th Apr 20221:36 pmRNSRemoval of Reg S restrictions from common stock
28th Mar 20227:00 amRNSGrant of Share Options
21st Mar 20227:00 amRNSResults twelve months ended 31 December 2021
24th Jan 20227:00 amRNSNew contract awards
21st Jan 20227:00 amRNSExercise of Options
6th Dec 20217:00 amRNSNew K-cup Orders in Q4 Exceed Expectations
2nd Nov 20213:37 pmRNSExercise of Options
25th Oct 20214:18 pmRNSRemoval of Regulation S restrictions
11th Oct 20217:00 amRNSLarge Central Bank Order
13th Sep 202110:27 amRNSHolding(s) in Company
25th Aug 202111:23 amRNSRemoval of Regulation S restrictions
21st Jul 20217:00 amRNSBanknote cleaning system also deactivates Covid-19
14th Jun 20217:00 amRNSAnnual General Meeting Update
17th May 20215:12 pmRNSShare Buy-Back
7th May 20214:49 pmRNSShare Buy-Back
6th May 20212:58 pmRNSShare Buy-Back
4th May 20215:51 pmRNSPosting of Annual Report and Accounts, AGM Notice
26th Apr 20211:45 pmRNSExercise of Options
22nd Apr 20217:00 amRNSNew Lottery Contracts
21st Apr 20217:00 amRNSEnhanced sensor capability contract
19th Apr 20211:46 pmRNSExercise of Options
8th Apr 20217:00 amRNSAllowance of Banknote Disinfection Patent
1st Apr 20213:29 pmRNSExercise of Options and Director/PDMR Shareholding
22nd Mar 20217:35 amRNSAudited Results for the 12 months ended 31 Dec 20
10th Feb 20217:00 amRNSExercise of Options
9th Feb 20212:11 pmRNSAppointment of Director
2nd Feb 20217:00 amRNSSecond phase of contract for sensor development
1st Feb 20213:33 pmRNSExercise of Options
20th Jan 20217:00 amRNSExercise of Options and Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.